(Q36965659)

17 August 2017

1 reference

title

Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates (English)

1 reference

17 August 2017

1 reference

Polascik TJ

1

1 reference

17 August 2017

publication date

9 October 2007

1 reference

Prostate Cancer and Prostatic Diseases

17 August 2017

published in

1 reference

17 August 2017

volume

11

1 reference

17 August 2017

issue

1

1 reference

17 August 2017

page(s)

13-19

1 reference

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501019

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501019

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501019

Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501019

Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501019

Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501019

Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501019

Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501019

Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501019

Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501019

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501019

Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501019

Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501019

Recommendations for zoledronic acid treatment of patients with bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501019

Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501019

Practical Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in Patients With Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501019

Alendronate for the Treatment of Osteoporosis in Men

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501019

Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501019

7 January 2021

The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501019

7 January 2021

Risk of fracture after androgen deprivation for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501019

7 January 2021

Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501019

7 January 2021

Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501019

7 January 2021

Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501019

7 January 2021

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501019

7 January 2021

The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4501019

7 January 2021

Identifiers

DOI

10.1038/SJ.PCAN.4501019

1 reference

17 August 2017

1 reference